Why you should sell Moderna (MRNA)

Companies like Moderna (MRNA) and Pfizer (PFE) has been unexpectedly releasing high efficacy results. Many investors remain skeptical of the releasing of the results.

The Moderna vaccine is 94.5% effective against coronavirus, according to early data released Monday by the company, making it the second vaccine in the United States to have a stunningly high success rate.

Last week, Pfizer announced that early data show its vaccine is more than 90% effective against the disease.

In Moderna’s trial, 15,000 study participants were given a placebo, which is a shot of saline that has no effect. Over several months, 90 of them developed Covid-19, with 11 developing severe forms of the disease.

Another 15,000 participants were given the vaccine, and only five of them developed Covid-19. None of the five became severely ill.

The company says its vaccine did not have any serious side effects. A small percentage of those who received it experienced symptoms such as body aches and headaches. Moderna plans to apply to the US Food and Drug Administration for authorization of its vaccine soon after it accumulates more safety data later this month.

Fauci says he expects the first Covid-19 vaccinations to begin “towards the latter part of December, rather than the early part of December.”

There won’t be a vaccine for everyone

There won’t be enough vaccines for everyone. The highest priority groups, which include health care workers, the elderly, and people with underlying medical conditions, will get the vaccine first.

The data is still early and more questions are to be asked.

Invest in Relief Therapeutics (OTC:RLFTF) instead

A small company Relief Therapeutics (OTC:RLFTF) is developing a therapeutic VIP drug called RLF-100 or Aviptadil, data going back decades has shown this drug to be highly effective. The company is developing it for use in severe COVID-19 patients.

Their drug candidate works by using a multimodal mechanism of action that uniquely target the pathways (inhibition of viral replication, deterrence of inflammatory cytokines, prevention of cell death and upregulation of surfactant production) attacked by the SARS-CoV-2 virus (COVID-19), preventing acute lung injury (ALI) which potentially can stop the replication of the virus.

The company is now conducting Phase 3 and previous results and data shows that this drug is highly promising.

Where to put $1,000 right now

STOP BUYING STOCKS RIGHT NOW … And start taking a serious look at options, the investment vehicle that is driving stocks like Tesla and Apple to historically unprecented highs. 

Subscribe below to get insight into options trades!

Jay Lorrence
Jay Lorrence

Investor of 12 years and Managing Editor of Money Midnight, a news outlet focused on highly profitable investment ideas and bold underground research.

Articles: 233

Newsletter Updates

Enter your email address below to subscribe to our newsletter